[Edaily Reporter Kim Hyung-il ] #DongBang Medical Co., Ltd. has obtained product approval in Brazil for its hyaluronic acid filler. This approval lays the groundwork for the company to sell the product locally.
DongBang Medical Co., Ltd. CI. (Photo courtesy of DongBang Medical Co., Ltd.)
According to the Financial Supervisory Service’s electronic disclosure system on the 10th, DongBang Medical Co., Ltd. announced that its product, “PHD HA Filler,” received marketing authorization from Brazil’s National Health Surveillance Agency (ANVISA). The authorization decision was made on the 9th (local time), and the company received the approval letter on the same day.
With this approval, DongBang Medical Co., Ltd. is now authorized to sell PHD HA Filler in Brazil. Brazil is one of the major aesthetic and medical markets in Latin America. Through this product approval, DongBang Medical Co., Ltd. has completed the regulatory procedures required to sell its products in the local market.
The collaboration between Samsung Group and HyundaiMotor Group is expanding beyond the supply of electric vehicle batteries to include joint design and the development of next-generation technologies.…
LG H&H(051900)is acquiring the remaining shares of Viva Wave, the operator of the color cosmetics brand HINS, to make it a wholly-owned subsidiary. This move is seen as a strategic effort to create a …
Hancom WITH(054920)is unveiling an authentication technology that uses artificial intelligence (AI) to analyze user behavior and continuously verify identity and security trustworthiness even while th…
